ACZ885 (canakinumab), a new II-1 beta blocking monoclonal antibody has a beneficial effect in children with systemic juvenile idiopathic arthritis (sjia)

Nicolino Ruperto, Pierre Quartier, Nico Wulffraat, Pat Woo, Anna Loy, Richard Mouy, Berent Prakken, Brigitte Bader-Meunier, Emanuele Noseda, Christiane Rordorf, Alberto Martini

Research output: Contribution to journalMeeting AbstractAcademic

Original languageEnglish
Pages (from-to)S942-S943
JournalArthritis and Rheumatism
Volume58
Issue number9
Publication statusPublished - Sept 2008

Cite this